AMVAC Chemical Corporation

All figures are consolidated American Vanguard Corporation. Sources: earnings releases furnished on Form 8-K for FY2022 (March 2023), FY2023 (March 2024) and FY2025 (March 2026); Form 10-K FY2025. FY2021 and FY2022 gross profit are shown on the reclassified basis presented in the FY2023 release so that the series is comparable.

Income statement

Revenue CAGR FY2021–FY2025: -2.0% (analyst-calculated). From the FY2022 peak the decline is 15.5%.

Commentary. The income statement shows a business that lost operating leverage in three steps. In FY2023, destocking and Chinese generic oversupply cut sales by 5% while R&D and regulatory spending rose to USD 38.0 million and interest expense tripled to USD 12.6 million. In FY2024, gross margin collapsed nine points: USD 21.4 million of inventory reserves, a product recall tied to Dacthal, and under-absorption, alongside USD 50.4 million of impairments (goodwill, SIMPAS, intangibles) and USD 20.2 million of transformation cost. FY2025 was a repair year: sales fell a further 6% but gross margin recovered to 28.6% as inventory reserves dropped to USD 3.8 million and procurement improved; SG&A fell USD 9.0 million and R&D/regulatory fell USD 9.5 million. The net loss still reached USD 49.9 million because of a USD 21.0 million write-off of all remaining goodwill, USD 9.7 million of product-liability charges and USD 18.5 million of interest. Adjusted EBITDA has been flat at about USD 39 million for two years; the improvement is in quality (fewer add-backs: "other one-time charges" fell from USD 60.8 million to USD 3.9 million) rather than level.

Balance sheet

Net debt excludes operating lease liabilities (USD 17.4 million at end-FY2025). All bank debt was classified as long-term in each year.

Commentary. Net debt rose from USD 31 million to USD 162 million in three years while equity halved. The drivers were a USD 77 million fall in customer prepayments from end-2022 to end-2025, a FY2023 inventory build, USD 49.5 million of share repurchases in FY2022–FY2023 executed near the top of the cycle, and operating losses. Tangible book value at end-FY2025 was approximately USD 53.7 million (equity less intangibles), about USD 1.88 per share on 28.5 million shares (analyst-calculated). After the March 2026 refinancing, total debt was approximately USD 267.6 million and cash USD 43.9 million at June 30, 2026 (Q2 2026 earnings call); net debt was USD 223.7 million per the slides and USD 224.7 million per the call transcript.

Cash flow

Commentary. Cumulative free cash flow over FY2023–FY2025 was negative USD 99 million. FY2025 operating cash flow before working-capital changes was roughly break-even (USD -1.0 million per the 10-K), with the outflow coming from lower prepayments (USD -19.6 million) and programme accrual payments (USD -17.4 million), partly funded by stretching payables (USD +15.4 million). Capex of USD 3.9 million is about one-fifth of depreciation and amortization — sustainable only briefly for a company running six plants. Management said on the FY2025 call that 2026 free cash flow "could be positive."

Ratios (analyst-calculated on year-end balances)

ROIC = operating income taxed at 25% in profitable years (untaxed in loss years) divided by debt plus equity. The company's own leverage figure at mid-2026 was 4.6x net debt to EBITDA (Q2 2026 slides).

Commentary. The cash conversion cycle of roughly 200 days is the central financial weakness: the company carries six to seven months of sales in net working capital. The apparent FY2025 improvement is largely payables stretch (87 days versus about 60 historically); the Q2 2026 materials note supplier financing has since been cut by half, which helps supplier relationships but absorbs cash. Interest cover of about 2x on adjusted EBITDA will tighten in 2026 because the first-lien loan carries SOFR (3.0% floor) plus 8.25%.

Most recent interim results (2026)

Sources: Q1 and Q2 2026 earnings releases (May 6 and August 10, 2026); Q1 2025 release. Q1 2025 gross margin is inferred from the stated 500-basis-point improvement.

Management guidance. FY2026: net sales USD 530–550 million and adjusted EBITDA USD 44–48 million, reaffirmed on August 10, 2026. With H1 at USD 240.3 million and USD 16.9 million, the midpoint requires H2 sales of about USD 300 million (+11% on H2 2025's USD 270 million) and H2 adjusted EBITDA of about USD 29 million (versus about USD 25 million in H2 2025). Management cites shifted cotton orders, a third-quarter order book it called "pretty nice," July price increases, and savings from the LA plant and HQ move. By 2028: revenue run-rate above USD 600 million, double-digit EBITDA margin, leverage of 3.0x.

Consensus. Not available from verified primary sources beyond the Q2 revenue miss noted above.

Bull case

1. Self-help is real and measurable. Gross margin rose from 22% to 30% in six quarters while sales fell; opex is down; inventory is down USD 43 million from end-2023; controls are remediated. Each further point of gross margin is worth about USD 5 million of EBITDA.

2. The equity is a small residual on a serviceable enterprise. At about USD 275 million of enterprise value, the business trades near 6x forward adjusted EBITDA and half of sales. If the 2028 targets are met (say USD 60 million-plus of EBITDA and USD 180 million of net debt), the equity value changes by multiples, not percentages.

3. The commercial engine is being rebuilt by people who have done it before. The CEO, U.S. Crop President and others come from Albaugh, a larger post-patent competitor; the Syngenta and Sipcam deals show the acquisition and in-licensing model restarting without straining the balance sheet.

Bear case

1. The capital structure consumes the recovery. Estimated cash interest of about USD 29 million plus even minimal capex leaves little free cash from USD 46 million of EBITDA. Net debt rose USD 28–30 million in Q2 2026 alone. Deleveraging to 3.0x needs both EBITDA growth and a working-capital release that the channel is resisting.

2. The forecasting record is poor and the year is back-end loaded. Guidance has been missed three years running, and Q2 2026 missed consensus by 13%. A second-half shortfall would bring the stepped-down covenants and the minimum-liquidity test into view, with a lender nominee already on the board.

3. The portfolio is ageing under regulatory fire. Dacthal is gone, PCNB is being exited, organophosphates face a tolerance petition, DCPA claims are uninsured, and capex at a fifth of depreciation does not suggest renewal of the manufacturing base.

Catalysts and monitorables (next 12 months)

• Q3 2026 results (expected early-to-mid November 2026): whether cotton and price increases deliver the implied H2 step-up.

• Year-end 2026 customer prepayment level and net debt.

• Closing and sales contribution of the Syngenta brands; further bolt-ons.

• First-lien covenant headroom and any amendment; step-down in loan margin if leverage improves.

• USEPA decisions on organophosphate registration review; any filed DCPA personal-injury suits; DBCP trial outcomes in Delaware.

• Recovery of the USD 7.6 million contamination claim from the counterparty.

• NYSE continued-listing position if the share price approaches USD 1.00.

• New CFO's first guidance cycle (FY2026 results, expected March 2027).

• Resolution of the international holding structure and any disposal of international units.

• FMC's strategic review, for both industry consolidation and the Axis landlord relationship.

Analyst verdict. AMVAC Chemical Corporation is a sound niche manufacturing franchise inside a strained capital structure. The operating evidence of the past eighteen months is better than the share price implies: margins have been rebuilt without help from the market, costs and inventory are lower, the control failures of 2024 are fixed, and a credible commercial team is in place. The specialty business is growing and the U.S. crop franchise has stopped shrinking. Those are genuine achievements by the Kaye management team.

Against that, the March 2026 refinancing solved a maturity problem by importing a cost problem. At an all-in rate above 11% on the first lien, lenders now receive most of the cash the business generates, sit on the board through a designated director, and hold covenants that tighten into 2028. Equity is about one-fifth of enterprise value and trades at roughly a quarter of book and near tangible book — a valuation that says the market assigns a meaningful probability to a debt-for-equity outcome or a dilutive raise. The company's guidance record does not yet justify giving it the benefit of the doubt, and the 2026 plan depends on a second half materially stronger than the first.

The investment question is therefore narrow: can adjusted EBITDA reach the mid-USD 50 millions and working capital fall toward 30% of sales before the 2028 covenant steps? If yes, the equity is deeply mispriced and a refinancing at conventional rates would transfer substantial value back to shareholders. If no, the lenders own the outcome. For a commercial counterparty, supplier or strategic partner, AMVAC remains a going concern with real assets, registrations and customer relationships, but credit terms and continuity planning should reflect a leveraged turnaround. The next two quarterly reports — Q3 2026 and the year-end prepayment and debt position — will be the most informative data points since the refinancing.

---

Verification status. Figures cited to Forms 10-K, DEF 14A and 8-K exhibits were taken from the filings themselves. Product active-ingredient identifications, pre-2020 deal details, competitor R&D ratios, market-size figures, ESG ratings, analyst coverage and multi-year share-price returns require confirmation before external use.